Case | HBS Case Collection | 2001
by Robert J. Dolan
Abgenix has a unique method for generating antibodies useful in treating a number of diseases, including cancer. In early 2000, the company's cancer has performed very well in animal testing and is moving to early stage human testing. Abgenix must decide whether to sell the product development program to a large pharmaceutical company or to enter into a joint venture to push the product ahead.
Keywords: Product Development; Marketing Strategy; Health Testing and Trials; Risk and Uncertainty; Technological Innovation; Innovation Strategy; Science-Based Business; Biotechnology Industry;
Citation:
Dolan, Robert J. "Abgenix and the XenoMouse." Harvard Business School Case 501-061, January 2001.
View Profile »View Publications »
Background Note | HBS Case Collection | 2009 (Revised from original 2005 version)
Principles of Pricing
Robert J. Dolan and John T. Gourville
Keywords: Price; Marketing Strategy; Value;
Case | HBS Case Collection | 2007 (Revised from original 1983 version)
Milford Industries (A)
Robert J. Dolan and Benson P. Shapiro
Keywords: Managerial Roles; Salesforce Management; Resignation and Termination; Performance Evaluation;
Background Note | HBS Case Collection | 2003 (Revised from original 1999 version)
Pricing: A Value-Based Approach
Robert J. Dolan
Keywords: Price; Customers;